Skip to Content

Nymox Pharmaceutical Corp NYMXF

Morningstar Rating
$0.19 0.00 (0.27%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NYMXF is trading at a 97% premium.
Price
$0.19
Fair Value
$8.87
Uncertainty
Extreme
1-Star Price
$6.93
5-Star Price
$8.50
Economic Moat
Qbqyk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYMXF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.19
Day Range
$0.160.22
52-Week Range
$0.051.28
Bid/Ask
$0.16 / $0.20
Market Cap
$17.30 Mil
Volume/Avg
10,217 / 19,176

Key Statistics

Price/Earnings (Normalized)
0.44
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
3

Valuation

Metric
NYMXF
Price/Earnings (Normalized)
0.44
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
NYMXF

Financial Strength

Metric
NYMXF
Quick Ratio
0.03
Current Ratio
0.25
Interest Coverage
−81.58
Quick Ratio
NYMXF

Profitability

Metric
NYMXF
Return on Assets (Normalized)
−372.15%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
NYMXF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WmvwzfxcQvkb$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
WmrwtvnbkYzlbg$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
PyvlbmmqgSryhrr$121.2 Bil
Moderna Inc
MRNA
YbkzcfgmGttl$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
NpkmpcjLndrbgz$33.0 Bil
argenx SE ADR
ARGX
SlpwyqjqkQqk$27.9 Bil
BioNTech SE ADR
BNTX
BcgflshtDkwgb$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
NgtsvfkrDfwshmb$16.1 Bil
United Therapeutics Corp
UTHR
NdvnccjPbzg$14.3 Bil
Incyte Corp
INCY
ShyfqynqVrcwdb$12.5 Bil

Sponsor Center